Selective targeting of HER2-overexpressing solid tumors with a next-generation CAR-T cell therapy.

3041Background: Conventional chimeric antigen receptor T cell (CAR-T) therapies have achieved limited clinical success in the treatment of solid tumors, in part due to the challenges of identifying...